RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.

@article{Mirschberger2013RG7116AT,
  title={RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.},
  author={Christian Mirschberger and Christian Schiller and Michael Schraeml and Nikolaos Dimoudis and Thomas Friess and Christian A. Gerdes and Ulrike Reiff and Valeria Lifke and Gabriele Hoelzlwimmer and Irene Kolm and Karl-Peter Hopfner and G. Niederfellner and Birgit Bossenmaier},
  journal={Cancer research},
  year={2013},
  volume={73 16},
  pages={5183-94}
}
The EGF receptor (EGFR) HER3 is emerging as an attractive cancer therapeutic target due to its central position in the HER receptor signaling network. HER3 amplifies phosphoinositide 3-kinase (PI3K)-driven tumorigenesis and its upregulation in response to other anti-HER therapies has been implicated in resistance to them. Here, we report the development and characterization of RG7116, a novel anti-HER3 monoclonal antibody (mAb) designed to block HER3 activation, downregulate HER3, and mediate… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Fcengineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells

  • SchlaethM, S Berger, S Derer, K Klausz, LohseS, DechantM
  • Cancer Sci 2010;101:1080–8
  • 2010
Highly Influential
14 Excerpts

Similar Papers

Loading similar papers…